We are live on ! Find out more
Candriam SCA

Candriam SCA Portfolio holdings

AUM $22.5B Turnover 10.3%
1-Year Est. Return 50.38%
 

Candriam is a Luxembourg asset manager with sustainable investing at its core, run as a subsidiary of New York Life Investments, with Belgian bank Belfius holding a minority stake. It was previously Dexia Asset Management and took the Candriam name in 2014, short for "Conviction AND Responsibility In Asset Management", after New York Life's asset management arm acquired it. Its funds span bonds, stocks, absolute return strategies and asset allocation, and its portfolios exclude controversial weapons, thermal coal and tobacco. In 2021 it bought a majority stake in the European real estate manager Tristan Capital Partners.

This Fund
S&P 500
This Quarter Est. Return
+6.07%
1 Year Est. Return
+50.38%
3 Year Est. Return
+175.97%
5 Year Est. Return
+212.01%
10 Year Est. Return
+804.12%
AUM
$22.5B
AUM Growth
+$301M
Cap. Flow
-$416M
Cap. Flow %
-1.85%
Top 10 Hldgs %
34.05%
Holding
699
New
21
Increased
252
Reduced
270
Closed
51
Avg Time Held
6.2 years
Top 10 Avg Time Held
3.9 years
Top 20 Avg Time Held
3.4 years

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$98.2M
2
META icon
Meta Platforms (Facebook)
META
+$82.9M
3
NOW icon
ServiceNow
NOW
+$70.4M
4
INTC icon
Intel
INTC
+$58.4M
5
CRM icon
Salesforce
CRM
+$54.9M

Top Sells

Rank Stock Value
1
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$102M
2
PANW icon
Palo Alto Networks
PANW
+$102M
3
ABBV icon
AbbVie
ABBV
+$68.9M
4
AMZN icon
Amazon
AMZN
+$57M
5
NVDA icon
NVIDIA
NVDA
+$54.1M

Sector Composition

Rank Sector Weight
1 Technology 41.06%
2 Healthcare 24.01%
3 Financials 9.02%
4 Communication Services 7.08%
5 Consumer Discretionary 6.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
TTWO icon
126
Take-Two Interactive
TTWO
$40B
$35.1M 0.16%
168,471
+158,371
+1,568% +$36.6M
2017 Q2
37 quarters
SYK icon
127
Stryker
SYK
$118B
$35.1M 0.16%
126,875
-34,869
-22% -$11M
2014 Q4
47 quarters
NTRA icon
128
Natera
NTRA
$41.8B
$34.9M 0.15%
84,048
-1,629
-2% -$512K
2022 Q3
16 quarters
MDGL icon
129
Madrigal Pharmaceuticals
MDGL
$9.8B
$34.8M 0.15%
68,842
-3,279
-5% -$1.73M
2025 Q1
6 quarters
DGX icon
130
Quest Diagnostics
DGX
$28.8B
$34.2M 0.15%
146,410
+26,172
+22% +$6.05M
2014 Q4
47 quarters
LAUR icon
131
Laureate Education
LAUR
$4.69B
$34.2M 0.15%
891,775
-574,786
-39% -$21.6M
2025 Q1
6 quarters
TXN icon
132
Texas Instruments
TXN
$269B
$34M 0.15%
121,099
+23,509
+24% +$6.5M
2014 Q4
47 quarters
IONS icon
133
Ionis Pharmaceuticals
IONS
$4.66B
$33.8M 0.15%
755,024
+310,005
+70% +$17.6M
2016 Q3
40 quarters
RYTM icon
134
Rhythm Pharmaceuticals
RYTM
$7.45B
$33.7M 0.15%
352,278
-80,747
-19% -$8.62M
2024 Q2
9 quarters
CAT icon
135
Caterpillar
CAT
$261B
$32.8M 0.15%
40,319
+1,740
+5% +$1.48M
2014 Q4
47 quarters
ALL icon
136
Allstate
ALL
$66.9B
$32.5M 0.14%
145,845
-24,488
-14% -$6.21M
2016 Q1
42 quarters
EW icon
137
Edwards Lifesciences
EW
$61.6B
$32.1M 0.14%
370,875
-292,909
-44% -$26M
2016 Q1
42 quarters
BLK icon
138
Blackrock
BLK
$185B
$31.9M 0.14%
30,070
+15,173
+102% +$16.6M
2024 Q4
7 quarters
USB icon
139
US Bancorp
USB
$94.2B
$31.6M 0.14%
545,661
-201,122
-27% -$12.6M
2014 Q4
47 quarters
NU icon
140
Nu Holdings
NU
$61.4B
$31.6M 0.14%
2,484,400
+2,137,400
+616% +$30.3M
2025 Q2
5 quarters
VRDN icon
141
Viridian Therapeutics
VRDN
$3.38B
$31.6M 0.14%
1,526,806
-180,892
-11% -$3.86M
2024 Q1
10 quarters
EL icon
142
Estee Lauder
EL
$39.4B
$31.5M 0.14%
338,834
+22,385
+7% +$2.04M
2014 Q4
47 quarters
SNDX icon
143
Syndax Pharmaceuticals
SNDX
$822M
$31.5M 0.14%
1,670,510
-25,530
-2% -$516K
2023 Q1
14 quarters
KRG icon
144
Kite Realty
KRG
$5.04B
$31M 0.14%
1,265,726
+801,541
+173% +$21.6M
2025 Q3
4 quarters
TFC icon
145
Truist Financial
TFC
$59.4B
$31M 0.14%
666,518
+2,016
+0.3% +$102K
2019 Q4
27 quarters
MIRM icon
146
Mirum Pharmaceuticals
MIRM
$5.98B
$30.9M 0.14%
359,633
-16,510
-4% -$1.72M
2024 Q2
9 quarters
BKNG icon
147
Booking.com
BKNG
$117B
$30.3M 0.13%
185,145
-121,154
-40% -$22.8M
2014 Q4
47 quarters
COF icon
148
Capital One
COF
$116B
$30.2M 0.13%
156,048
+93,558
+150% +$19.6M
2014 Q4
47 quarters
SNOW icon
149
Snowflake
SNOW
$99B
$30.1M 0.13%
88,232
-5,344
-6% -$1.65M
2021 Q2
21 quarters
BMO icon
150
Bank of Montreal
BMO
$118B
$30.1M 0.13%
178,726
-30,412
-15% -$5.37M
2016 Q1
42 quarters

Similar funds

Candriam SCA's Q3 2026 Portfolio in Review

As of Q3 2026, Candriam SCA held 699 positions worth $22.5B, up 1.4% from $22.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Candriam SCA's Q3 2026 filing shows 21 new, 252 increased, 270 reduced and 51 closed positions. Its largest new stake was Zenas BioPharma: 654,833 shares worth $17.7M. The largest sale was Alphabet (Google) Class A, an estimated $102M.

By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 38% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q3 2026 buy was Zenas BioPharma: 654,833 shares worth $17.7M.
  • Candriam SCA added most to Abbott in Q3 2026, an estimated $98.2M increase.
  • Candriam SCA's biggest Q3 2026 reduction was Alphabet (Google) Class A, cutting an estimated $102M.
  • Candriam SCA fully exited StoneX in Q3 2026, selling an estimated $46.1M.
  • Candriam SCA's ten largest holdings make up 34% of its $22.5B portfolio in Q3 2026.
  • Candriam SCA opened 21 new positions and closed 51 in Q3 2026.
  • Candriam SCA's portfolio value rose 1.4% quarter-over-quarter to $22.5B.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.